article_1_hero
article_continue

Approximately 15% to 25% of breast cancers have overexpression of the human epidermal growth factor receptor 2 (HER2) protein, increased HER2 gene amplification, or both. These breast cancers are called HER2-positive (HER2+) and are characterized by aggressive growth, greater likelihood to spread, and poor prognosis. There are, however, treatment options designed specifically for HER2+ breast cancer.

KADCYLA (ado-trastuzumab emtansine) is a HER2-targeted antibody-drug conjugate (ADC) that combines the antibody effects of HERCEPTIN (trastuzumab) with the cytotoxic effects of DM1. These two entities, which are linked together by a molecule called MCC, are designed to target HER2+ cells directly. Together, MCC and DM1 comprise emtansine. KADCYLA is the first ADC designed to target a solid tumor, and it represents a major advancement in oncology therapy.

Select the icons below to learn more about antibody-drug conjugates.
What is an ADC?
What are the benefits of an ADC?

Select the hotspots on the timeline below for more information on the Food and Drug Administration (FDA) approvals for KADCYLA and the clinical trials described in the Prescribing Information that support the two FDA-approved indications.